Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma
Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvironment (TiME). However, the PDAC TiME is heterogeneous and ha...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1324093/full |
| _version_ | 1797337212934684672 |
|---|---|
| author | Zachary Gao Joseph Azar Huili Zhu Sophia Williams-Perez Sung Wook Kang Sung Wook Kang Sung Wook Kang Celia Marginean Mark P. Rubinstein Shalini Makawita Hyun-Sung Lee Hyun-Sung Lee Hyun-Sung Lee E. Ramsay Camp E. Ramsay Camp E. Ramsay Camp |
| author_facet | Zachary Gao Joseph Azar Huili Zhu Sophia Williams-Perez Sung Wook Kang Sung Wook Kang Sung Wook Kang Celia Marginean Mark P. Rubinstein Shalini Makawita Hyun-Sung Lee Hyun-Sung Lee Hyun-Sung Lee E. Ramsay Camp E. Ramsay Camp E. Ramsay Camp |
| author_sort | Zachary Gao |
| collection | DOAJ |
| description | Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvironment (TiME). However, the PDAC TiME is heterogeneous and harbors favorable tumor-infiltrating lymphocyte (TIL) populations. Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop within non-lymphoid tissue under chronic inflammation in multiple contexts, including cancers. Our current understanding of their role within the PDAC TiME remains limited; TLS are complex structures with multiple anatomic features such as location, density, and maturity that may impact clinical outcomes such as survival and therapy response in PDAC. Similarly, our understanding of methods to manipulate TLS is an actively developing field of research. TLS may function as anti-tumoral immune niches that can be leveraged as a therapeutic strategy to potentiate both existing chemotherapeutic regimens and potentiate future immune-based therapeutic strategies to improve patient outcomes. This review seeks to cover anatomy, relevant features, immune effects, translational significance, and future directions of understanding TLS within the context of PDAC. |
| first_indexed | 2024-03-08T09:07:13Z |
| format | Article |
| id | doaj.art-3e6e51bdf9ba427abab3c7c4585d3485 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T09:07:13Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3e6e51bdf9ba427abab3c7c4585d34852024-02-01T04:31:58ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13240931324093Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinomaZachary Gao0Joseph Azar1Huili Zhu2Sophia Williams-Perez3Sung Wook Kang4Sung Wook Kang5Sung Wook Kang6Celia Marginean7Mark P. Rubinstein8Shalini Makawita9Hyun-Sung Lee10Hyun-Sung Lee11Hyun-Sung Lee12E. Ramsay Camp13E. Ramsay Camp14E. Ramsay Camp15Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesThe Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United StatesSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesThe Pelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United StatesSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United StatesDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United StatesBaylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, United StatesPancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvironment (TiME). However, the PDAC TiME is heterogeneous and harbors favorable tumor-infiltrating lymphocyte (TIL) populations. Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop within non-lymphoid tissue under chronic inflammation in multiple contexts, including cancers. Our current understanding of their role within the PDAC TiME remains limited; TLS are complex structures with multiple anatomic features such as location, density, and maturity that may impact clinical outcomes such as survival and therapy response in PDAC. Similarly, our understanding of methods to manipulate TLS is an actively developing field of research. TLS may function as anti-tumoral immune niches that can be leveraged as a therapeutic strategy to potentiate both existing chemotherapeutic regimens and potentiate future immune-based therapeutic strategies to improve patient outcomes. This review seeks to cover anatomy, relevant features, immune effects, translational significance, and future directions of understanding TLS within the context of PDAC.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1324093/fulltertiary lymphoid structurespancreatic adenocarcinomapancreatic cancertranslational abilityimmune microenvironment |
| spellingShingle | Zachary Gao Joseph Azar Huili Zhu Sophia Williams-Perez Sung Wook Kang Sung Wook Kang Sung Wook Kang Celia Marginean Mark P. Rubinstein Shalini Makawita Hyun-Sung Lee Hyun-Sung Lee Hyun-Sung Lee E. Ramsay Camp E. Ramsay Camp E. Ramsay Camp Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma Frontiers in Immunology tertiary lymphoid structures pancreatic adenocarcinoma pancreatic cancer translational ability immune microenvironment |
| title | Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma |
| title_full | Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma |
| title_fullStr | Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma |
| title_full_unstemmed | Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma |
| title_short | Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma |
| title_sort | translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma |
| topic | tertiary lymphoid structures pancreatic adenocarcinoma pancreatic cancer translational ability immune microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1324093/full |
| work_keys_str_mv | AT zacharygao translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT josephazar translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT huilizhu translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT sophiawilliamsperez translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT sungwookkang translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT sungwookkang translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT sungwookkang translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT celiamarginean translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT markprubinstein translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT shalinimakawita translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT hyunsunglee translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT hyunsunglee translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT hyunsunglee translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT eramsaycamp translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT eramsaycamp translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma AT eramsaycamp translationalandoncologicsignificanceoftertiarylymphoidstructuresinpancreaticadenocarcinoma |